Reducing Adenoviral Patient-Infected Days (RAPID): Tolerance of a Single In-Office Administration of Betadine for Acute Adenoviral Conjunctivitis

Shorter, Ellen1; Whiteside, Meredith2; Harthan, Jennifer3; Hartwick, Andrew T.4; Huecker, Julie5; Margolis, Mathew5; Bossie, Tim6; Johnson, Spencer7; Migneco, Mary5; Morettin, Christina5; Olson, Christian K.8; Van Zyl, Tave9; Gordon, Mae5; Than, Tammy P.10.


PURPOSE

• “Reducing Adenoviral Patient-Infected Days” (RAPID) is a double-masked randomized planning study of a one-time administration of 5% povidone-iodine (PVP-I 5%; ophthalmic betadine) compared to preservative-free artificial tears (AT) for the treatment of presumed adenoviral conjunctivitis (Ad-Cs).
• We compared tolerability of a single treatment of PVP-I 5% to AT.

METHODS

• Eligibility included: informed consent, age ≥ 18, red eye with symptoms ≤ 4 days, and positive AdenoPlus rapid immunoassay test.
• Participants were randomized to treatment with 4-5 drops of either PVP-I 5% or AT after 1 drop of proparacaine 0.5%.
• After 2 minutes, the ocular surface was thoroughly lavaged with sterile saline irrigation solution.
• Participants rated overall discomfort in the study eye from 0 (not at all bothersome) to 10 (very bothersome) before and immediately after treatment.
• Unmasked clinicians rated perceived patient discomfort in the treated eye from 0 (no discomfort) to 10 (very high discomfort) after treatment.
• Clinicians rated corneal staining before, immediately after and 1-2 days after treatment using the NEI fluorescein staining scale of 0 to 4 in five corneal zones. Composite scores were calculated by summing all five zones with a maximum score of 20.

RESULTS

Table 1 Corneal Staining Before and After Treatment

<table>
<thead>
<tr>
<th></th>
<th>Before Treatment (Day 0 Visit)</th>
<th>Immediately After Treatment (Day 0 Visit)</th>
<th>Follow-Up (Day 1-2 Visit)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT group</td>
<td>1.8 (SD ± 2.4) n=26</td>
<td>1.6 (SD ± 2.4) n=26</td>
<td>2.2 (SD ± 2.4) n=23</td>
</tr>
<tr>
<td>PVP-I 5% group</td>
<td>1.3 (SD ± 1.9) n=30</td>
<td>3.3 (SD ± 3.3)* n=30</td>
<td>1.3 (SD ± 1.9) n=28</td>
</tr>
</tbody>
</table>

In the AT group, no difference in corneal staining was detected between pre-treatment, immediate post-treatment day 0 or follow-up day 1-2.

In the PVP-I 5% group, a significant increase in corneal staining occurred immediately following treatment on day 0 that returned to pre-treatment levels by the first follow-up visit (day 1-2).

Table 2: Patient rated discomfort before and immediately after treatment and clinician estimated post-treatment discomfort.

<table>
<thead>
<tr>
<th></th>
<th>Patient Reported Discomfort</th>
<th>Clinician Estimated Discomfort Immediately After Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before Treatment</td>
<td>Immediately After Treatment</td>
</tr>
<tr>
<td>AT group (n=26)</td>
<td>6.7 (SD ± 2.6)</td>
<td>3.3 (SD ± 2.8)**</td>
</tr>
<tr>
<td>PVP-I 5% group (n=30)</td>
<td>6.0 (SD ± 3.0)</td>
<td>6.2 (SD ± 2.8)</td>
</tr>
</tbody>
</table>

In the AT group, there was a decrease in participant-reported discomfort immediately after treatment on day 0.

In the PVP-I 5% group, there was no difference in participant-reported discomfort before and immediately after treatment on day 0.

Unmasked clinicians rated the PVP-I 5% group with higher perceived discomfort than the AT group.

CONCLUSION

• Ophthalmic PVP-I 5% has been shown to be safe and tolerable through its use as a surgical scrub and prophylactic use before intraocular injections and procedures.
• Anecdotal reports suggest that corneal staining and ocular discomfort are barriers to its use by clinicians in treating Ad-Cs.
• We did not detect an increase in participant-reported ocular discomfort immediately after treatment with ophthalmic PVP-I 5% in this study.
• There was a reduction in participant-reported discomfort immediately after AT treatment.
• There was an increase in corneal staining immediately after treatment with PVP-I 5% which returned to pre-treatment levels by the day 1-2 visit.
• These results suggest that ophthalmic PVP-I 5% is well tolerated by patients with presumed Ad-Cs.

SUPPORT

• This work was supported by a National Eye Institute Center R34 Grant (EY023633-01A1), a National Eye Institute Center Core Grant (P30EY002687) and an unrestricted grant to the Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness.
• Clinical Trial Registration: # NCT02472223

https://clinicaltrials.gov/ct2/show/NCT02472223